International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 8, 2011, Pages 1271-1274

  Vasikaran, Samuel ^a,b   Cooper, Cyrus ^c,d   Eastell, Richard ^e   Griesmacher, Andrea ^f   Morris, Howard A ^g   Trenti, Tommaso ^h   Kanis, John A ⁱ  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NORTHERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^g UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^h Nuovo Ospedale S Agostino   (Italy)

ⁱ UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

bone mineral density; bone turnover markers; clinical risk factors; fracture risk; osteoporosis; reference standard

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; PROCOLLAGEN; PROCOLLAGEN TYPE I AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BONE DENSITY; BONE TURNOVER; FRACTURE; HEALTH CARE ORGANIZATION; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; STANDARD; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BONE AND BONES; COLLAGEN TYPE I; HUMANS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; REFERENCE VALUES; RISK FACTORS;

EID: 80051752915     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.602     Document Type: Article

References (36)

1. Harvey N, Dennison E, Cooper C. Osteoporosis: Impact on health and economics. Nat Rev Rheumatol 2010;6:99-105.
2. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
3. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N, et al. A reference standard for the description of osteoporosis. Bone 2008;42:67-475.
4. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97.
5. Nguyen ND, Pongchaiyakul C, Center JR, Eisman JA, Nguyen TV. Identification of high-risk individuals for hip fracture: A 14-year prospective study. J Bone Miner Res 2005;20:1921-8. (Pubitemid 41532777)
6. Dargent-Molina P, Douchin MN, Cormier C, Meunier PJ, Bréart G for the EPIDOS study group. Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS prospective study. Osteoporos Int 2002;13:593-9. (Pubitemid 34790633)
7. Vasikaran S, Eastell R, Bruyére O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. Osteoporos Int 2011;22:391-420.
8. Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gärdsell P, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study of women. J Bone Miner Res 1995;10:1823-9.
9. Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 1996;11:1531-8. (Pubitemid 26331009)
10. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-93. (Pubitemid 38787393)
11. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporos Int 2000;11:76-82. (Pubitemid 30099514)
12. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high-risk of fracture: The OFELY study. J Bone Miner Res 2005;20:1813-9. (Pubitemid 41361882)
13. van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study. Br Med J 1996;312:482-3. (Pubitemid 26061239)
14. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD. Under carboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: The EPIDOS study. J Clin Endocrinol Metab 1997;82:719-24. (Pubitemid 27106576)
15. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: The Dubbo osteoporosis epidemiology study. J Bone Miner Res 2005;20: 579-87. (Pubitemid 40393065)
16. Bauer DC. Biochemical markers of bone turnover: The study of osteoporotic fracture. In: Eastell R, Baumann M, Hoyle N, Wieczorek L, editors. Bone markers -biochemical and clinical perspectives. London: Martin Dunitz Ltd, 2001;219-23.
17. Dobnig H, Piswanger-Solkner JC, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, et al. Hip and non-vertebral fracture prediction in nursing home patients: Role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 2007;92: 1678-86. (Pubitemid 46997171)
18. Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P. Predictors of fractures in elderly women. Osteoporos Int 2000;11: 134-40. (Pubitemid 30168798)
19. Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993;91:1769-74. (Pubitemid 23127383)
20. Chapurlat RD, Garnero P, Bréart G, Meunier PJ, Delmas PD. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: The EPIDOS study. Bone 2000;27:283-6. (Pubitemid 30458823)
21. Luukinen H, Kakonen S-M, Pettersson K, Koski K, Laippala P, Lovgren T, et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 2000;15:2473-8.
22. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 2000;15:1526-36. (Pubitemid 30484522)
23. Greenfield DM, Hannon RA, Eastell R. The association between bone turnover and fracture risk (Sheffield Osteoporosis study). In: Eastell R, Baumann M, Hoyle N, Wieczorek L, editors. Bone markers -biochemical and clinical perspectives. London: Martin Dunitz Ltd; 2000;225-36.
24. Garnero P, Cloos P, Sornay-Rendu E, Qvist PE, Delmas PD. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study. J Bone Miner Res 2002;17:826-33. (Pubitemid 34441899)
25. Bruyére O, Collette J, Delmas PD, Rouillon A, Roux C, Seidel L, et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal women. Maturitas 2003;44:259-65. (Pubitemid 36412177)
26. Melton III LJ, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003;18:312-8. (Pubitemid 36125923)
27. Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, et al.; Osteoporotic Fractures in Men (MrOS) Research Group. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: The MrOS study. J Bone Miner Res 2009;24:2032-8.
28. Szulc P, Delmas P. Biochemical markers of bone turnover: Potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008;19:1683-704.
29. Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ. Bone turnover markers and prediction of fracture: A prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010;25:393-403.
30. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20: 1244-53. (Pubitemid 40863814)
31. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6. (Pubitemid 37294942)
32. Reginster J-Y, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344-51. (Pubitemid 38177616)
33. Sarkar S, Reginster J-Y, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401. (Pubitemid 38787394)
34. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 2004;19:1250-8. (Pubitemid 41094365)
35. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, et al.; The HORIZON-PFT Research Group. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24:1544-51.
36. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001;47: 1443-50. (Pubitemid 32678824)